Immutep(US:IMMP) Globenewswire·2025-09-08 12:00Core Viewpoint - Immutep Limited is set to present findings from the EFTISARC-NEO Phase II trial at the CTOS 2025 Annual Meeting, highlighting the potential of eftilagimod alpha in treating soft tissue sarcoma [1][2]. Group 1: Trial Overview - EFTISARC-NEO is the first study to assess eftilagimod alpha in a neoadjuvant setting, combined with radiotherapy and KEYTRUDA for soft tissue sarcoma patients [2]. - The trial is being conducted by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and is primarily funded by a Polish government grant [5]. Group 2: Disease Context - Soft tissue sarcoma (STS) is classified as an orphan disease with significant unmet medical needs and poor patient prognosis [4]. - In the United States, approximately 13,520 new STS cases are expected in 2025, with around 5,420 deaths projected [4]. Group 3: Company Background - Immutep is a late-stage biotechnology company focused on developing innovative immunotherapies for cancer and autoimmune diseases, particularly leveraging LAG-3 [6]. - The company aims to maximize shareholder value while providing new treatment options for patients in need [6].